KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

West Pharmaceutical Services (WST) Consolidated Net Income (2016 - 2025)

West Pharmaceutical Services' Consolidated Net Income history spans 17 years, with the latest figure at $128.2 million for Q4 2025.

  • For Q4 2025, Consolidated Net Income changed 0.08% year-over-year to $128.2 million; the TTM value through Dec 2025 reached $479.3 million, changed 0.27%, while the annual FY2025 figure was $479.3 million, 0.27% changed from the prior year.
  • Consolidated Net Income for Q4 2025 was $128.2 million at West Pharmaceutical Services, down from $137.9 million in the prior quarter.
  • Across five years, Consolidated Net Income topped out at $183.0 million in Q2 2022 and bottomed at $86.4 million in Q1 2025.
  • The 5-year median for Consolidated Net Income is $134.0 million (2023), against an average of $137.0 million.
  • The largest annual shift saw Consolidated Net Income soared 120.76% in 2021 before it crashed 32.43% in 2022.
  • A 5-year view of Consolidated Net Income shows it stood at $147.7 million in 2021, then plummeted by 32.43% to $99.8 million in 2022, then skyrocketed by 33.97% to $133.7 million in 2023, then decreased by 4.19% to $128.1 million in 2024, then increased by 0.08% to $128.2 million in 2025.
  • Per Business Quant, the three most recent readings for WST's Consolidated Net Income are $128.2 million (Q4 2025), $137.9 million (Q3 2025), and $126.8 million (Q2 2025).